Jost W H
Parkinson-Klinik Ortenau, Kreuzbergstr. 12-16, 77709, Wolfach, Deutschland.
Nervenarzt. 2017 Apr;88(4):373-382. doi: 10.1007/s00115-017-0309-z.
Since the 1960s many substance classes have been introduced for treatment of idiopathic Parkinson's disease. The most important and effective medication is levodopa (L-dopa) always in combination with a decarboxylase inhibitor. In addition, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, catechol-o-methyltransferase (COMT) inhibitors, N‑methyl-D-aspartate (NMDA) antagonists and very rarely anticholinergics are administered depending on the motor symptoms, age and a multitude of other factors. Fortunately, within the substance classes there are various preparations, which also have different effects. In order that the advantages of the individual medications can be exploited and undesired effects and interactions can be avoided, one must come to terms with the complex data and the pharmacology of the medication. In addition important aspects are interactions and reciprocal actions. In the foreseeable future, different substance classes are to be expected.
自20世纪60年代以来,已经引入了许多类药物用于治疗特发性帕金森病。最重要且有效的药物是左旋多巴(L-多巴),它总是与一种脱羧酶抑制剂联合使用。此外,根据运动症状、年龄和许多其他因素,还会使用多巴胺激动剂、单胺氧化酶B(MAO-B)抑制剂、儿茶酚-O-甲基转移酶(COMT)抑制剂、N-甲基-D-天冬氨酸(NMDA)拮抗剂,很少使用抗胆碱能药物。幸运的是,在各类药物中都有多种制剂,它们也有不同的作用。为了能够利用每种药物的优点并避免不良影响和相互作用,人们必须熟悉这些复杂的数据和药物的药理学。此外,重要的方面是相互作用和相互影响。在可预见的未来,预计会出现不同的药物类别。